Molecular Partners (NASDAQ:MOLN) Price Target Cut to $3.75 by Analysts at JPMorgan Chase & Co.

Molecular Partners (NASDAQ:MOLN) had its price target decreased by JPMorgan Chase & Co. from $4.00 to $3.75 in a research report released on Monday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Molecular Partners in a research report on Monday, December 1st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Molecular Partners presently has a consensus rating of “Hold” and an average target price of $7.88.

Molecular Partners Trading Down 2.9%

Molecular Partners stock opened at $4.39 on Monday. Molecular Partners has a 1-year low of $3.36 and a 1-year high of $5.95. The firm has a market capitalization of $177.27 million, a PE ratio of -2.29 and a beta of 1.08. The firm’s 50 day simple moving average is $3.97 and its 200 day simple moving average is $3.82.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.05. Research analysts forecast that Molecular Partners will post -1.93 earnings per share for the current year.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.